La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Lyra Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Lyra Therapeutics..

Lyra Therapeutics (NASDAQ:LYRA) Azioni, Catena delle Opzioni

Lyra Therapeutics

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Lyra Therapeutics Inc

Health Care

Press Releases

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Earnings

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

News

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

Analyst Ratings

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Contracts

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

LYRA

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

Biofrontera

Cocrystal Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

IM Cannabis

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NLS Pharmaceutics

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Pulmatrix

Q/C Technologies

SenesTech

Traws Pharma

TherapeuticsMD

VYNE Therapeutics

cbdMD

HC Wainwright & Co.

Jefferies

B of A Securities

BTIG

Comments

Lyra Therapeutics

Lyra Therapeutics (LYRA) Opzioni

Lyra Therapeutics (NASDAQ:LYRA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO